Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe and Simvastatin in Dyslipidemia of Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus with stable antidiabetic treatment since at least three months~* Total cholesterol concentrations \>135mg/dl and/or concomitant lipid lowering therapy with HMGCoA inhibitors~* Serum creatinine ≤1.5mg/dl~* Urinary albumin excretion rate \< 200μg/min~* Written informed consent~Exclusion Criteria:~* History of myocardial infarction, stroke or hospital admission for angina within the previous 6 months~* History of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting~* Clinically manifest heart failure (grade III or above according to New York Heart Association criteria)~* Poor glycemic control (HbA1C \>11%)~* Primary hyperlipidemia~* Uncontrolled thyroid diseases~* Infectious disease within 4 weeks of starting~* Acute liver disease or hepatic dysfunction~* Inflammatory muscle disease or evidence of muscle problems~* Concurrent treatment with systemic steroids, androgens, cyclosporin and other immunosuppressive drugs, fibrates, high-dose niacin or cholestyramine~* Pregnancy or lactating~* Women of childbearing potential without following a scientifically accepted form of contraception~* Life-threatening conditions or terminal concomitant diseases other than diabetes~* Specific contraindications or history of hypersensitivity to the study drugs or other statins~* Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial~* Evidence of an uncooperative attitude~* Any evidence that patient will not be able to complete the trial follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).